| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/23/2003 | WO2001051472A9 New imidazole derivatives |
| 01/23/2003 | US20030018987 Animal model for use in the diagnosis and treatment of eating, apoptosis and infectious disorders |
| 01/23/2003 | US20030018984 IGF-I expression system and methods of use |
| 01/23/2003 | US20030018207 Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin |
| 01/23/2003 | US20030018199 Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018193 Beta-alanine derivatives and their use as receptor anatgonists |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018176 Dry acid-chitosan complexes |
| 01/23/2003 | US20030018083 Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine |
| 01/23/2003 | US20030018081 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
| 01/23/2003 | US20030018075 Threonine, or mixture with methionine; side effect reduction |
| 01/23/2003 | US20030018072 Utilization of dialkylfumarates |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018064 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 01/23/2003 | US20030018061 Novel remedies with the use of beta 3 agonist |
| 01/23/2003 | US20030018053 Substituted indolealkanoic acids |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018028 Combination therapy for type II diabetes or Syndrome X |
| 01/23/2003 | US20030018021 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists |
| 01/23/2003 | US20030018017 Method of treatment of type I diabetes |
| 01/23/2003 | US20030018016 Cell adhesion inhibitors |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030017999 Synergistic mixture of isovaleryl carnitine and polysaccharides |
| 01/23/2003 | US20030017969 Methods and pharmaceutical compositions for healing wounds |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017509 Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus |
| 01/23/2003 | US20030017488 Method for testing a therapeutic or preventive agent for hyperlipidemia |
| 01/23/2003 | US20030017205 Nutritional tablet of caplet with a coating of a film forming polymer and folic acid; rapid release |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2454181A1 Use of corticotroph-derived glycoprotein hormone to induce lipolysis |
| 01/23/2003 | CA2453784A1 A core formulation |
| 01/23/2003 | CA2453782A1 Core formulation comprising troglitazone and a biguanide |
| 01/23/2003 | CA2453775A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 01/23/2003 | CA2453574A1 Transgenic plants expressing cobalamin binding proteins |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453515A1 Linear and cyclic melanocortin receptor-specific peptides |
| 01/23/2003 | CA2453403A1 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453308A1 Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide |
| 01/23/2003 | CA2453285A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | CA2453216A1 Amphiphilic star-like macromolecules for drug delivery |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453027A1 Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| 01/23/2003 | CA2452610A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | CA2452417A1 Compositions comprising the biologicially active peptide ysl |
| 01/23/2003 | CA2451670A1 Enteral formulations |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2448553A1 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/22/2003 | EP1277760A1 Method of searching for arteriosclerosis inhibitors and shrinkers |
| 01/22/2003 | EP1277753A1 Thiazolidinedione derivative and its use as antidiabetic |
| 01/22/2003 | EP1277745A1 Novel stable crystal of thiazolidinedione derivative and process for producing the same |
| 01/22/2003 | EP1277736A1 Novel bicyclic compounds |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277475A1 Bone-strengthening agents, food compositions for strengthening bone and feed compositions for strengthening bone |
| 01/22/2003 | EP1277469A1 Activators for peroxisome proliferator-activated receptor |
| 01/22/2003 | EP1277412A1 Pet food composition for regulating body weight and preventing obesity and related disorders in pets |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276731A2 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht 1a activity |
| 01/22/2003 | EP1276730A2 Thiazolidinedione analogues and their use for the treatment of diabetes |
| 01/22/2003 | EP1276729A1 New neurokinin antagonists for use as medicaments |
| 01/22/2003 | EP1276714A2 Cyclic carboxylic acids as integrin antagonists |
| 01/22/2003 | EP1276710A1 New compounds, their preparation and use |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1276465A2 Improved water-insoluble drug particle process |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP0937085B1 Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
| 01/22/2003 | CN1392798A Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides, and vaccine composition comprising same |
| 01/22/2003 | CN1392797A High mannose proteins and method of making mannose proteins |
| 01/22/2003 | CN1392796A Polyhydroxylated benzene-containing compounds |
| 01/22/2003 | CN1392264A Process for preparing easy body absorption protein ion and health food produced therefrom |
| 01/22/2003 | CN1392263A Method for preparing easy body absorption protein-calcium by enzyme and health food produced by said protein-calcium |
| 01/22/2003 | CN1392137A New cyclic alpha-amino-gamma hydroxy amide compound, its preparing method and medicinal composition containing said compound |
| 01/22/2003 | CN1391953A Biological food therapeutic health article containing metallothionein for treating diabetes and complication and its preparation |
| 01/22/2003 | CN1391929A Common man fat reducing food containing micro alternative biological electric field regulated bacterial strain |
| 01/22/2003 | CN1391923A Fat reducing health care product and its preparing method |
| 01/22/2003 | CN1391906A Novel lipase inhibitor |
| 01/22/2003 | CN1391903A Microcapsule coated trace element product and its producing method |
| 01/22/2003 | CN1391900A Microcapsule coated liposoluble vitamin product and its producing method |
| 01/22/2003 | CN1391898A Water soluble vitamin product coated with micro capsule and its producing method |
| 01/22/2003 | CN1391893A Process for preparing simvastation drip pill |
| 01/22/2003 | CN1391890A Oral melbine hydrocloride slow-releasing prepn and its preparing method |
| 01/22/2003 | CN1391839A Fat woman fat-reducing food contaiing micro alternating biological electric field regulated bacterial strain |
| 01/22/2003 | CN1391838A Common woman fat-reducing food containing micro alternating biological electric field regualted bacterial strain |
| 01/22/2003 | CN1391837A Fat man fat-reducing food containing micro alternating biological electric field regualted bacterial strain |
| 01/22/2003 | CN1099293C Hypolipemic medicine and its preparing process and application |
| 01/22/2003 | CN1099290C Chinese medicine formula and preparation for promoting blood circulation and reducing blood fat |
| 01/21/2003 | US6509499 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |